2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - R02-R05
Treatment Considerations, Combination Therapy, Drug Development, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, MPN, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

528 A Phase 2 study of canakinumab combined with JAK inhibitor therapy in patients with myelofibrosis

Andrew T Kuykendall, MD, Rupali Roy Roy Bhave, MD2, Marina Kremyanskaya, MD, PhD3, Abdulraheem Yacoub, MD4, Aaron T. Gerds, MD, MS5, Ronald Paquette I, MD6, Jeanne Palmer, MD7, Kathryn Johnson, DNP8, Heidi Kosiorek, MS9, Amylou C Dueck, PhD10, Carolyn Mead-Harvey, MS11, Gillian Sanchez12, Rami Komrokji, MD13, Ruben Mesa, MD14, Ronald Hoffman, MD15, John O. Mascarenhas, MD16
1 Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, United States
2 Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 University of Kansas Medical Center, Kansas City, Kansas, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cedars Sinai Medical Center, Los Angeles, California, United States
7 Mayo Clinic, Scottsdale, Arizona, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Mayo Clinic, Scottsdale, Arizona, United States
10 Mayo Clinic, Scottsdale, Arizona, United States
11 Mayo Clinic, Scottsdale, Arizona, United States
12 Icahn School of Medicine at Mount Sinai, New York, New York, United States
13 Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, United States
14 Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
15 Icahn School of Medicine at Mount Sinai, New York, New York, United States
16 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Introduction:

IL-1b is a master regulator of inflammation that is overexpressed in MPNs, preferentially supports the MPN mutant stem cell, and controls the production of numerous chemokines and inflammatory cytokines that have been implicated in fibrogenesis, inflammatory symptoms and disease progression. Canakinumab is a fully human monoclonal antibody that binds to and neutralizes IL-1b and has already been approved for rare inflammatory disorders profile.

Based upon these data, a 2-part, phase 2 study of canakinumab in pts with MF was designed. Part 1 investigated the use of canakinumab as a single agent in pts with MF previously treated with, or ineligible to receive a JAK inhibitor (JAKi). Results from part 1 presented at ASH in 2025 in conjunction with preclinical models, justified proceeding to part 2 of the study which assessed the addition of canakinumab to a stable dose of JAKi in pts with a suboptimal response. Herein, we present the results of part 2 of this study.

Methods:

NCT05467800 is an MPN Research Consortium (MPN-RC) ongoing, 2-part, phase 2 study of canakinumab in pts with MF. Part 2 enrolled pts with MF currently being treated with a JAKi ≥16 weeks on a stable dose for ≥12 weeks who had the potential to benefit from additional therapy. Upon enrollment, canakinumab (200 mg SC on day 1 of 21-day cycles) was added to ongoing JAKi therapy. Primary response assessment occurred at week 24 (C9D1).

Eligible pts had platelets (plt)>25 x 109/L, and a need for additional MF-directed therapy due to: hemoglobin (hgb)<10 g/dL, transfusion dependency, splenomegaly (palpated ≥5cm below left costal margin or volume ≥ 450 cm3) and/or MF-SAF version 4.0 TSS>10.

The primary endpoint was overall response rate (ORR) including CR, PR or CI after 8 cycles (24 weeks). A Bayesian optimal phase 2 (BOP2) design was used to monitor both efficacy and toxicity.

Results:

In part 2, 13 pts were enrolled and treated. Enrollment has completed with 11 pts remaining on treatment at time of data cut-off. 

Median age was 64y [46-78]. Baseline JAKi was ruxolitinib in 10 (76.9%) pts and momelotinib in 3 (23.1%) pts. Median duration of JAKi prior to study was 57.1 weeks. Median hgb was 11.2 g/dL, median plt count was 159 x 109/L, and median WBC was 8.7 x109/L. One patient (7.7%) was transfusion dependent.  Median MF-SAF TSS at baseline was 19 (range:4-42). Median spleen volume at baseline was 1244.3cm3 (range:766cm3-3950.8cm3). Pts received a median of 9 cycles (range:4-14). 

At week 12, 6 of 12 (50%) evaluable pts responded with 2 pts achieving an anemia response, 5 pts achieving a symptom response and 1 patient achieving both. Among 2 pts who achieved an anemia response, 1 achieved transfusion independence for >12 weeks while the other had a >2g/dL improvement in hgb. At week 24, 4 of 7 (57.1%) evaluable pts responded with 2 achieving an anemia response, 3 achieving a symptom response and 1 achieving both. Notably, 1 pt achieved an anemia response at week 24 despite an increase in spleen volume which occurred after JAKi discontinuation. One (7.7%) pt experienced progression of disease due to an increase in spleen volume.

Overall, spleen volume remained stable from baseline (median spleen volume 1276 cm3) to week 12 (1353.5cm3). Hgb, WBC and Plt counts also remained stable. Among pts with baseline MF SAF≥10, 7/11 (64%) had improvement in MF-SAF from baseline at week 24 or at last timepoint. At week 12 and 24, 9 (75%) and 5 (83%) pts reported improvement in symptoms per PGIC, respectively.

The most common adverse events (AEs) were anemia (31%), thrombocytopenia (38%), fatigue (31%), and night sweats (31%) and were often attributed to underlying disease. One patient died after a cardiac arrest that was deemed to not be related to canakinumab.  

 

Conclusions:

The IL-1b inhibitor, canakinumab, in combination with a JAKi resulted in consistent symptom improvement and exhibited a beneficial impact on cytopenias in MF pts who had previously had a suboptimal response to their JAKi alone. Canakinumab in combination with a JAKi was well-tolerated and resulted in superior responses compared to canakinumab monotherapy despite having little impact on splenomegaly. This data warrants further exploration of canakinumab and the IL-1β/IRAK pathway for the treatment of MF and MPNs. Updated results will be presented at the ASH Annual Meeting 2026. 

Andrew T Kuykendall, MD: Novartis - Honoraria; Incyte - Honoraria; Karyopharm - Honoraria; Disc Medicine - Honoraria; GlaxoSmithKline - Honoraria; Geron - Honoraria; Cogent - Honoraria; Bristol Myers Squibb - Honoraria; Blueprint - Honoraria; PharmaEssentia - Honoraria; Sobi - Honoraria; Kartos/Ipsen - Research Funding; Geron - Research Funding; Incyte - Research Funding; Blueprint - Research Funding; Protagonist - Research Funding; Novartis - Research Funding; AJAX/Eli Lilly - Research Funding; GlaxoSmithKline - Research Funding; Prelude - Research Funding; Bristol Myers Squibb - Research Funding; Takeda - Research Funding; Dompei - Research Funding; Janssen - Research Funding; Disc Medicine - Research Funding; AbbVie - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); Protagonist - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Calytrix - Consultancy (Includes expert testimony); Damora - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Silence Therapeutics - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony)